NCT00836251|Completed
Effects of Antipsychotic Medications on Energy Intake and Expenditure
DLW
Loading search results
DLW
Sponsor study identifier
observational
15
1 country
1
Study Start
April 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2008
Actual (reported)Study Completion
June 2008
Actual (reported)Aim 1: To evaluate the effect of antipsychotic treatment group on Activity Energy Expenditure. The project hypothesizes that subjects treated with olanzapine will demonstrate a greater decrease in AEE over time than subjects treated with ziprasidone, due at least in part to sedating effects of olanzapine. Aim 2: To evaluate the effect of antipsychotic treatment group on Energy Intake. The project hypothesizes that subjects treated with olanzapine will demonstrate a greater increase in EI over time than subjects treated with ziprasidone, based on higher histamine type 1 (H1) receptor affinity of olanzapine and the relationship between H1 affinity and hunger and/or satiety.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 2006
Date type not reportedThis date has not been verified as actual or estimated.
June 2008
Actual (reported)June 2008
Actual (reported)February 3, 2009
Actual (reported)February 4, 2009
Actual (reported)treatment-induced changes in Total Energy Expenditure (TEE), Activity Energy Expenditure (AEE), and Energy Intake (EI)
12 weeks
schizophrenia
0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Males and females, ages 18-80, diagnosed with schizophrenia or schizoaffective disorder
Washington University School of Medicine
St Louis, Missouri, 53110, United States
John W Newcomer, MD
Florida Atlantic University
Ginger Nicol, MD
Washington University School of Medicine
15 participants (actual enrollment reported by the registry).
First Submitted
February 3, 2009
First Posted
February 4, 2009
Study Start
April 2006
Date type not reportedThis date has not been verified as actual or estimated.
Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder
Contact the study team to confirm eligibility.
Primary Completion
June 2008
Actual (reported)Study Completion
June 2008
Actual (reported)Last Updated
March 13, 2014
Record last verified: 2014-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: